NPCE Stock Tumbles Despite Positive One-Year Data From NAUTILUS Trial

NeuroPace (NPCE) recently announced promising preliminary one-year results from its pivotal NAUTILUS trial, evaluating the RNS System in patients with idiopathic generalized epilepsy (IGE). This study marks a major milestone, as it is the first to assess a brain-responsive neuromodulation system in this patient population.This development positions NeuroPace as a leader in advancing neuromodulation therapies for generalized epilepsy, a segment historically underserved by current medical technologies. With t ...